SOLICITATION NOTICE
B -- Funtional-selective ligands for the D2 dopamine receptor
- Notice Date
- 3/23/2010
- Notice Type
- Presolicitation
- NAICS
- 541690
— Other Scientific and Technical Consulting Services
- Contracting Office
- Department of Health and Human Services, National Institutes of Health, National Institute on Drug Abuse, Station Support/Simplified Acquisitions, 31 Center Drive, Room 1B59, Bethesda, Maryland, 20892
- ZIP Code
- 20892
- Solicitation Number
- NOI-1531865
- Archive Date
- 4/21/2010
- Point of Contact
- Liem T Nguyen, Phone: 3014358780
- E-Mail Address
-
ln18x@nih.gov
(ln18x@nih.gov)
- Small Business Set-Aside
- N/A
- Description
- The National Institute of Health (NIH), National Institute on Drug Abuse (NIDA) Office of Acquisitions, Station Support Simplified Acquisitions Branch on behalf of the National Institute of Neurological Disorders and Stroke (NINDS) intends to negotiate on a non-competitive basis with the Trustees of Columbia University in the City of New York, 630 west 168th Street, New York, NY 10032, for professional service to support the NINDS' study on neuropsychiatric and endocrine disorders. The North American Industry Classification System Code for this acquisition is 541690 and the business size standard is $7.0 million. This is a firm fixed-price type acquisition. The NINDS, Molecular Neuropharmacology Section has an on-going research on development, testing, and optimization of constructs and cell lines that stably express the appropriate quantities and ratios of D2 receptor and ß-arrestin-fusion proteins for robust bioluminescence resonance energy transfer (BRET) analysis for the R21 grant award "Functional-selective ligands for the D2 dopamine receptor." These include stable HEK293 cell lines expressing human ß-arrestin and mutants thereof fused to mVenus fluorescent protein with tetracycline-inducible expression of human dopamine D2 receptors fused to Rennila luciferase. These cell lines will be used by the Sibley laboratory and the NIH Chemical Genomics Center (NCGC) to conduct high throughout screens of small molecule libraries to identify novel allosteric modulators of D2 receptors. The proposed acquisition is associated with neuropsychiatric and endocrine disorders. Dopamine receptors (DARs) are involved in the etiology and/or therapy of a number of neuropsychiatric and endocrine disorders. For instance, all receptor-based anti-Parkinsonian drugs work via stimulating the D2 DAR subtype whereas all FDA-approved antipsychotic agents are antagonists of this receptor. Most drugs targeting the D2 DAR are problematic, however, either being less efficacious than desired or possessing limiting side effects, most of which are due to reactivity at other receptors. One approach towards improved receptor specificity is to identify allosteric ligands that bind to less-conserved regions of the receptor and therefore have the potential to be much more selective. The Trustees of Columbia University will develop cell lines that will be used in a BRET-based primary high throughput screening assay for a Molecular Libraries Probe Production Center Network approved project for ß-arrestin recruitment in response to dopamine D2 receptor activation. The proposed acquisition is based on a R21 Award 1R21NS067642-01 to the Sibley Laboratory (Intramural) and the Javitch Laboratory (Extramural). These studies are to be carried out within the NINDS Intramural Research Program and the NCGC in collaboration with the laboratory of Dr. Jonathan A. Javitch at the Columbia University College of Physicians and Surgeon. The Javitch laboratory was selected for collaboration and to provide the required constructs because of their internationally established expertise in structure-function studies of dopamine receptors and their pioneering application of BRET-based methods to receptor oligomerization and activation of G proteins and ß-arrestin, as well as an established collaboration with the Sibley laboratory, who has already tested the preliminary reagents developed in the Javitch laboratory and found that they will be suitable for the creation of the stably transfected cell line proposed for these studies. Based on the experience and the involvement of the Javitch laboratory with the on-going study, it is determined that the Javitch laboratory/ the Trustees of Columbia University is the unique and qualified vendor to perform the requirement. No other sources will satisfy the agency's requirement. The period of performance is to be six (6) months from date of award with option for one (1) twelve-month optional period. Place of performance is Bethesda, Maryland. No solicitation package will be issued. This notice of intent is not a request for competitive quotations; however, the Government will consider response submit to ln18x@nih.gov on or before 3:00 PM ET April 6, 2010. All information furnished must be in writing and must contain material in sufficient detail to allow the government to determine if the party can perform the requirement. A determination by the Government not to compete this proposed acquisition based upon responses to this notice is solely within the discretion of the Government. Information received will be considered solely for the purpose of determining whether to conduct a competitive procurement. In order to receive an award, contractors must be registered in and have valid certifications in the Central Contractor Registration (CCR), www.ccr.gov and the Online Representations and Certifications Application (ORCA) www.orca.bpn.gov. Please reference announcement number NOI-1531865 on all correspondence.
- Web Link
-
FBO.gov Permalink
(https://www.fbo.gov/spg/HHS/NIH/NIDA-2/NOI-1531865/listing.html)
- Place of Performance
- Address: Bethesda, Maryland, 20892, United States
- Zip Code: 20892
- Zip Code: 20892
- Record
- SN02100471-W 20100325/100324000104-a761cd4de514950333317af7003fbbdc (fbodaily.com)
- Source
-
FedBizOpps Link to This Notice
(may not be valid after Archive Date)
| FSG Index | This Issue's Index | Today's FBO Daily Index Page |